Initial antiretroviral therapy in chronically-infected HIV-positive adults

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 3, 2004, Pages 595-612

  Temesgen, Zelalem ^a   Cainelli, Francesca ^b   Warnke, David ^a   Koirala, Janak ^a  

^a MAYO CLINIC   (United States)

^b Southern Illinois University ^*

Author keywords

Antiretroviral drugs; Antiretroviral therapy; Highly active antiretroviral therapy (HAART); Initial antiretroviral regimen

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BILIRUBIN; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BONE DISEASE; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; ESOPHAGUS ULCER; FATIGUE; FEVER; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART BLOCK; HEMATURIA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSOMNIA; JAUNDICE; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; MALAISE; METABOLIC DISORDER; MOUTH ULCER; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEPHROLITHIASIS; NEUROTOXICITY; NEUTROPENIA; NIGHTMARE; OSTEOMALACIA; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PSYCHOSIS; RASH; REVIEW; SKIN DISCOLORATION; SKIN MANIFESTATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; THROMBOCYTOPENIA; VISUAL IMPAIRMENT; VOMITING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHRONIC DISEASE; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT OUTCOME;

EID: 1542609988     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.3.595     Document Type: Review

References (122)

1. PALELLA FJ Jr, DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. (1998) 338:853-860.
2. TORRES RA, BARR M: Impact of combination therapy for HIV infection on inpatient census. N. Engl. J. Med. (1997) 336:1531-1532.
3. CHAISSON MA, BERENSON L, LI W et al.: Accelerating decline in New York City AIDS mortality. In: 5th Conference on Retroviruses and Opportunistics Infections, Foundation for Retrovirology and Human Health, Chicago, USA (1998).
4. HOGG RS, O'SHAUGHNESSY MV, GATARIC N et al.: Decline in deaths from AIDS due to new antiretrovirals. Lancet (1997) 349:1294-1294.
5. MOUTON Y, ALFANDARI S, VALETTE M et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS (1997) 11:F101-F105.
6. BRODT HR, KAMPS BS, GUTE P, KNUPP B, STASZEWSKI S, HELM EB: Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS (1997) 11:1731-1738.
7. EGGER M, HIRSCHEL B, FRANCIOLI P et al.: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Br. Med. J. (1997) 315:1194-1199.
8. PALELLA FJ Jr, CHMIEL JS, MOORMAN AC, HOLMBERG SD: HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS (2002) 16(12):1617-1626.
9. ERON J, BENOIT S, JEMSEK J et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N. Engl. J. Med. (1995) 333:1662-1669.
10. KURITZKES DR, MARSCHNER I, JOHNSON VA et al.: Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind placebo-controlled trial AIDS (1999) 13:685-694.
11. STASZEWSKI S, KATLAMA C, HARRER T et al.: A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS (1998) 12(16):197-202.
12. BARDITCH-CROVO P, DEEKS SG, COLLIER A et al.: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2001) 45(10):2733-2739.
13. DELEHANTY J, WAKEFORD C, QUINN L et al.: A Phase I/II Randomized, Controlled Study of FTC Versus 3TC in HIV-Infecred Patients. In: 6th Conference on Ritroviruses and Opportunistic Infections, Foundation for Retrovirology and Human Health, Chicago, USA (1999) (Abstract 16).
14. PARAAMF, MEEHAN P, HOLDEN-WILTSE J, et al.: ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. Antimicrob. Agents Chemother. (1999) 43:1373-1378.
15. MAYERS D, RIDDLER S, STEIN D et al: A double-blind pilot study to evaluate the antiviral activity, tolerability and pharmacokinetics of DMP 266 alone and in combination with indinavir. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, USA (1996) (Abstract LB08A).
16. KITCHEN VS, SKINNER C, ARIYOSHI K et al.: Safety and activity of saquinavir in HIV infection. Lancet (1995) 345:952-955.
17. DANNER SA, CARR A, LEONARD JM et al.: A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. The European-Australian Collaborative Ritonavir Study Group. N. Engl. J. Med. (1995) 333:1528-1534.
18. GULICK RM, MELLORS JW, HAVLIR D et al.: Simultaneous versus sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. 100-Week follow-up. JAMA (1998) 280:35-41.
19. MARKOWITZ M, CONANT M, HURLEY A et al.: A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J. Infect. Dis. (1998) 177:1533-1540.
20. 3. In: 4th Conference on Ritroviruses and Opportunistic Infections, Foundation for Retrovirology and Human Health, Washington DC, USA (Abstract 508).
21. MURPHY RL, BRUN S, HICKS C et al.: ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 15:F1-F9.
22. SANNE I, PILIERO P, SQUIRES K, THIRY A, SCHNITTMAN S: AI424-007 Clinical Trial Group. Results of a Phase II clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J. Acquir. Immune Defic. Syndr. (2003) 32(1):18-29.
23. HAMMER SM, KATZENSTEIN DA, HUGHES M D et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N. Engl. J. Med. (1996) 335:1081-1090.
24. KATZENSTEIN DA, HAMMER SM, HUGHES MD et al.: The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. (1996) 335:1091-1098.
25. KURITZKES DR, MARSCHNER I, JOHNSON VA et al.: Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind placebo-controlled trial. AIDS (1999) 13:685-694.
26. FOUDRAINE NA, DE JONG JJ, JAN WEVERLING G et al.: An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS (1998) 12:1513-1519.
27. MOLINA JM,ACHENE G, FERCHAL F et al.: The ALBI Trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. J. Infect. Dis. (1999) 180:351-358.
28. CARR A, CHAUH J, HUDSON J et al.: A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: The OzCombo1 study. AIDS (2000) 14:1171-1180.
29. SQUIRES, KE, GULICK R, TEBAS P et al.: A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: Selection of thymidine analog regimen therapy (START I). AIDS (2000) 14:1591-1600.
30. ERON JJ, MURPHU RL, PETERSON D et al.: A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II). AIDS (2000) 14:1601-1610.
31. STASZEWSKI S, GALLANT JE, POZNIAK AL et al.: Efficacy and safety of tenofovir DF versus stavudine when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003) (Abstract 564b).
32. DEJESUS E, HERRERA G, TEOFILO E et al.: Efficacy and safety of abacavir (ABC) versus zidovudine (ZDV) in antiretroviral therapy naive adults with HIV-1 infection. In: Program and abstracts of the 43rd Annual ICAAC, Chicago, Illinois, USA (Abstract H-446).
33. RAFFI F, SAAG M, CAHN P et al.: A Randomized, double-blind, multicenter comparison of emtricitabine qd to stavudine BID in treatment naïve HIV-infected patients. In: Program and abstracts of the The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France (2003) (Abstract 38).
34. SANNE I, VAN DER HORST C, SHAW A et al.: Two randomized, controlled, equivalence trials of emtricitabine (FTC) to lamivudine (3TC). In: Program and abstracts of the XIV International AIDS Conference, Barcelona, Spain (2002) (Abstract TuPeB4432).
35. GULICK RM, RIBAUDO HJ, SHIKUMA CM et al.: ACTG 5095: A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France (2003) (Abstract 41).
36. GALLANT JE, RODRIGUEZ AE, WEINBERG W et al.: Early Non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009. In: Program and abstracts of the 43th Annual ICAAC, Chicago, USA (2003) (Abstract 1722a).
37. FARTHING C, KHANLOU H, YEH V: Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France (2003) (Abstract 43).
38. KING RW, KLABE RM, REID CD, ERICKSON-VIITANEN SK: Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob. Agents Chemother. (2002) 46(6):1640-1646.
39. MONTANER, JS, REISS P, COOPER D, VELLA S et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA (1998) 279(12):930-937.
40. HARRIS M, PATENAUDE P, COOPERBERG P et al.: Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. INCAS Study Group. Italy, Netherlands, Canada, Australia, and (United) States. J. Infect. Dis. (1997) 176(5):1388-1392.
41. SQUIRES K, forAthe ATLANTIC STUDY TEAM: The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, final 48 week data. In: Program and abstracts of the XIII International AIDS Conference, Durban, South Africa (2000) (Abstract LbPeB7046).
42. VAN DER VALK M, KASTELEIN JJ, MURPHY RL et al.: The Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 15(18):2407-2414.
43. PODZAMCZER D, FERRER E, CONSIGLIO E et al.: A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir. Ther. (2002) 7(2):81-90.
44. BARTLETT JA, JOHNSON J, HERRERA G et al.: Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001(CLASS) preliminary 48 week results. In: Program and abstracts of the The XIV International AIDS Conference, Barcelona, Spain (2002) (Abstract TuOrB1189).
45. STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. (1999) 341(25):1865-1873.
46. TASHIMA K, STASZEWSKI S, MORALES-RAMIREZ J et al.: 3-Year Durability Of Response With An Efavirenz (Efv)-Containing Regimen: 144 Week Follow-Up Of Study 006. In: Program and abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina (2001) Abstract no. 224.
47. MATTHEWS GV, SABIN CA, MANDALIA S et al.: Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: A cohort study. AIDS (2002) 16:53-61.
48. KEISER, P, NASSAR N, WHITE C, KOEN G, MORENO S: Comparison of Nevirapine-and Efavirenz- containing antiretrovral regimens in antiretroviral-naïve patients: A cohort study. HIV Clin. Trials (2002) 3(4):296-303.
49. COZZI-LEPRI A, PHILLIPS AN, D'ARMINIO MONFORTE AD et al.: Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian cohort naïve antiretrovirals (I.Co.N.A) study. J. Infect. Dis. (2002) 185:1062-1069.
50. NUNEZ M, SORIANO V, MARTIN-CARBONERO L et al.: SENC (Spanish efavirenz versus nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals. HIV Clin. Trials (2002) 3(3):186-194.
51. VAN LEITH F, HASSINK E, PHANUPHAK P et al.: Results of the 2NN Study: A randomized, comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. In: Program and abstracts of the 10th Conferenceon Retroviruses and Opportunistic Infections, Boston, USA (2003) (Abstract 176).
52. ROBBINS GK, DE GRUTTOLA V, SHAFER RW et al. For the AIDS Clinical Trials Group 384 Team: Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. N. Engl. J. Med. (2003) 349:2293-2303.
53. SHAFER RW, SNYDER SW, ROBBINS GK et al. For the AIDS Clinical Trials Group 384 Team: Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. N. Engl. J. Med. (2003) 349:2304-2315.
54. SENSION MG, FARTHING C, SHAFFER AG et al.: Challenges of antiretroviral treatment in transient and drug-using populations: The SUN study. AIDS Patient Care STDS (2001) 15:129.
55. MATHEZ D, BAGNARELLI P, GORIN I et al.: Reductions in viral load and increases in T lymphocyte numbers in treatment naïve patients with advanced HIV infection treated with ritonavir, zidovudine, and zalcitabine triple therapy. Antivir. Ther. (1997) 2:175.
56. STASZEWSKI S, KEISER P, MONTANER J et al.: Abacavir-lamivudine-zidovudine versus indinavir-lamivudine-zidovudine in antiretroviral-naive hiv-infected adults: A randomized equivalence trial. JAMA (2001) 285:1155-1163.
57. WALMSLEY S, BERNSTEIN B, KING M et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. (2002) 346:2039-2046.
58. SANNE I, CAHN P, PERCIVAL L, and the BMS-008 International Trial Group: Atazanavir versus nelfinavir in combination with stavudine and lamivudine in treatment-naive HIV-Infected Patients, 48-week results. In: Programs and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotheraphy, Chicago, USA (2001) (Abstract I-667).
59. SQUIRES KE, THIRY A, GIORDANO M: Atazanavir (ATV) QD and efavirenz (EFV) AQ with fixed-dose ZDV + 3TC: Comparison of antiviral efficacy and safety through Wk 24 (AI424-034). In: Programs and abstracts of the 42nd Interscience Conference on Antimicrobiol Agents and Chemotherapy, San Diego, USA (2002) (Abstract H-1076).
60. RODRIGUEZ-FRENCH A, BOGHOSSIAN J, GRAY GE et al, the NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. (2004) 35(1):22-32.
61. SCHURMANN D, GATHE J, SANNE J, WOOD R: Efficacy and safety of GW433908/ritonavir once daily in therapy-naïve subjects, 48 week results: The SOLO study. Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland. November 17-21 (2002) (Abstract PL14.4).
62. D'ARMINIO MONFORTE A, LEPRI AC, REZZA G et al.: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral-naïve patients. AIDS (2000) 14:499-507.
63. SULKOWSKI MS, THOMAS DL, MEHTA SH, CHAISSON RE, MOORE RD: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology (2002) 35(1):182-189.
64. NUNEZ M, LANA R, MENDOZA JL, MARTIN-CARBONERO L, SORIANO V: Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2001) 27(5)-426-431.
65. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000. MMWR Morb. Mortal. Wkly Rep. (2001) 49(51-52):1153-1156.
66. DE SANTIS M, CARDUCCI B, DE SANTIS L, CAVALIERE AF, STRAFACE G: Periconceptional exposure to efavirenz and neural tube defects. Arch. Intern. Med. (2002) 162(3):355.
67. FUNDARO C, GENOVESE O, RENDELI C, TAMBURRINI E, SALVAGGIO E: Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS (2002) 16(2):299-300.
68. ACETI A, PASQUAZZI C, ZECHINI B, DE BAC C, LIVERHAART Group: Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection. J. Acquir. Immune Defic. Syndr. (2002) 29(1):41-48.
69. BONFANTI P, LANDONIO S, RICCI E, The CISAI study group: Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2001) 27(3):316-318.
70. FELLAY J, BOUBAKER K, LEDERGERBER B et al.: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 358:1322-1327.
71. MATTHEWS GV, MOYLE GJ, MANDALIA S, BOWER M, NELSON M, GAZZARD BG: Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. J. Acquir. Immune Defic. Syndr. (2000) 24:310-315.
72. KUMAR P, RODRIGUEZ-FRENCH A, THOMPSON M et al.: Prospective study of hyperlipidemia in ART-naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T /lamivudine (3TC)/NFV (ESS40002). In: Program and abstract of the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA (2002):64 (Abstract 33).
73. TASHIMA K, STRYKER R, SKIEST D et al.: Lipid profiles & clinical lipodystrophy in study 006 patients. In: Programs and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotheraphy, San Diego, USA (1999) (Abstract 1304).
74. VAN DER VALK M, KASTELEIN JJ, MURPHY RL et al.: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 15:2407-2414.
75. VAN LETH F, PHANUPHAK P, GAZZARD B et al.: Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN Study). In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003):328 (Abstract 752).
76. PERIARD D, TELENTI A, SUDRE P et al.: Atherogenic dyslipidemia, in HIV-infected individuals treated with protease inhibitors. The Swiss HIV cohort study. Circulation (1999) 100:700-705.
77. DUBÉ MP, QIAN D, EDMONDSON-MELANÇON H et al.: Prospective, 48-week, intensive metabolic study of amprenavir-based therapy. Clin. Infect. Dis. (2002) 35:475-481.
78. SEGERER S, BOGNER JR, WALLI R, LOCH O, GOEBEL FD: Hyperlipidemia under treatment with proteinase inhibitors. Infection (1999) 27:77-81.
79. MOYLE GJ, BALDWIN C: Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (1999) 21:423-424.
80. CASTAGNA A, DRAGSTED UB, CHAVE JP et al.: The interim analysis of a phase iv randomised, open-label, multicentre trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg BID) versus saquinavir/ritonavir (1000/100 mg MID) in Adult HIV-1 infection: MaxCmin1 Trial. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistics Infections, Boston, USA (2002) (Abstract 752).
81. GATELL J, SQUIRES K, PILIERO P, SANNE I, WOOD R, SCHNITTMAN SM: Atazanavir (BMS-232632): Absence of serum lipid changes after 48 weeks of treatment in treatment-naive HIV-positive subjects (Trial AI424-007). Antivir. Ther. (2001) 6(Suppl.4):49.
82. DUBÉ MP, EDMONDSON-MELANCON H, QIAN D, AQEEL R, JOHNSON D, BUCHANAN TA: Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J. Acquir. Immune Defic. Syndr. (2001) 27:130-134.
83. CARR A, SAMARAS K, CHISHOLM DJ, COOPER DA: Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet (1998) 351:1881-1883.
84. DUBÉ MP, JOHNSON DL, CURRIER JS, LEEDOM JM: Protease inhibitor-associated hyperglycaemia. Lancet (1997) 350:713-714.
85. CARR A, SAMARAS K, BURTON S et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12:F51-F58.
86. MULLIGAN K, GRUNFELD C, TAI VW et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acquir. Immune Defic. Syndr. (2000) 23:35-43.
87. WALLI R, HERFORT O, MICHL GM et al.: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS (1998) 12:F167-F173.
88. BEHRENS G, DEJAM A, SCHMIDT H et al.: Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS (1999) 13:F63-F70.
89. MURATA H, HRUZ PW, MUECKLER M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. (2000) 275:20251-0254.
90. MILLER JE, EMERY S, FRENCH M et al.: The Australian prevalence survey of lipodystrophy syndrome. In: Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2000) (Abstract 201).
91. LICHTENSTEIN KA, WARD DJ, MOORMAN AC et al.: Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS (2001) 15:1389-1398.
92. BERNASCONI E, BOUBAKER K, SUDRE P et al.: Metabolic side effects of antiretroviral therapy in the Swiss Cohort Study. In: Programs and abstracts of the XIII International AIDS Conference, Durban, South Africa (2000) (Abstract ThOrB703).
93. GERVASONI C, RIDOLFO AL, TRIFIRO G et al.: Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS (1999) 13:465-471.
94. MALLAL SA, JOHN M, MOORE CB et al.: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS (2000) 14:1309.
95. MULLIGAN K, TAI VW, ALGREN H et al.: Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J. Acquir. Immune Defic. Syndr. (2001) 26:443-448.
96. SAINT-MARC T, PARTISANI M, POIZOT-MARTIN I, TOURAINE JL: Reversibility of peripheral fat wasting (lipodystrophy) on stopping stavudine therapy. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco (2000) (Abstract 52).
97. LONERGAN JT, HAVLIR D, BARBER E, MATHEWS WC: Incidence and outcome of hyperlactatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containing regimens. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA (2001) (Abstract 624).
98. JOHN M, MOORE CB, JAMES IR et al.: Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS (2001) 15:17-23.
99. BRINKMAN K, TER HOFSTEDE HJM, BURGER DM, SMEITINK JAM, KOOPMANS PP: Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS (1998) 12:1735-1744.
100. WALKER UI, SETZER B, VEENHOFF N: Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS (2002) 16(16):2165-2173.
101. GLESBY MJ: Bone disorders in human immunodeficiency virus infection. Clin. Infect. Dis. (2003) 37(Suppl. 2):S91-S95.
102. THOMAS J, DOHERTY SM: HIV infection-a risk factor for osteoporosis. J. Acquir. Immune Defic. Syndr. (2003) 33(3):281-291.
103. TEBAS P, POWDERLY WG, CLAXTON S et al.: Accelerated bone mineral loss in HIV-infiected patients receiving potent antiretroviral therapy. AIDS (2000) 14:F63-F67.
104. HOLMBERG SD, MOORMAN AC, WILLIAMSON JM et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet (2002) 360:1747-1748.
105. MARY-KRAUSE M, COTTE L, PARTISANI M, SIMON A, COSTAGLIOLA D: Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Alexandria, VA, USA. Foundation for Retrovirology and Human Health (2001) (Abstract 657).
106. FRIIS-MOLLER N, SABIN CA, WEBER R: Combination antiretroviral therapy and the risk of myocardial infarction. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. N. Engl. J. Med. (2003) 349(21):1993-2003.
107. BOZZETTE SA, AKE C, CARPENTER A et al.: Cardio- and cerebrovascular outcomes with changing process of anti-HIV therapy in 36,766 US veterans. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, Alexandria, VA, USA. Foundation for Retrovirology and Human Health (2002) (Abstract LB-9).
108. DEEKS SG, SMITH M, HOLODNIY M, KAHN JO: HIV-1 protease inhibitors. A review for clinicians. JAMA (1997) 277:145-153.
109. BECKER SL: The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opin. Investig. Drugs (2003) 12(3):401-412.
110. MOYLE G: The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs (2001) 61(1):19-26.
111. KEARNEY BP, ISAACSON E, SAYRE J, PLUMMER A, CHENG A: Didanosine and tenofovir DF drug-drug interaction: Assessment of didanosine dose reduction. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA, Alexandria, VA. Foundation for Retrovirology and Human Health (2003):245 (Abstract 533).
112. TABURET AM, PIKETTY C, GÉRARD L et al.: Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: A sub-study of Puzzle-2-ANRS 107 trial. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA. Alexandria, VA. Foundation for Retrovirology and Human Health, (2003):247 (Abstract 537).
113. D'AQUILA RT, SCHAPIRO JM, BRUN-VEZINET F, CLOTET B: Drug resistance mutations in HIV-1. Top. HIV Med. (2003) 11(3):92-96.
114. SORIANO V, DE MENDOZA C: Generic mechanisms of resistance to NRTI and NNRTI. HIV Clin. Trials (2002) 3(3):237-248.
115. TEBAS P, POWDERLY WG: Nelfinavir mesylate. Expert Opin. Pharmacother. (2000) 1:1429-1440.
116. TEBAS P, PATICK AK, KANE EM et al.: Virologic re-sponses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS (1999) 13:F23-28.
117. KEMPF D, KING M, BAUER E et al.: Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir/ritonavir or nelfinavir as initial therapy. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003) (Abstract 600).
118. CVETKOVIC RS, GAA KL: Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs (2003) 63(8):769-802.
119. PRADO JG, WRIN T, BEAUCHAINE J et al.: Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS (2002) 16(7):1009-1017.
120. COLONNO R, ROSE R, CIANCI C, ALDROVANDI G, PARKIN N, FRIBORG J: Emergence of atazanavir resistance and maintenance of susceptibility to other PIs is associated with a 150L substitution in HIV protease. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections Boston, Massachusetts, USA (2003) (Abstract 597).
121. COLONNO RJ. THIRY A. LIMOLI K. PARKIN N: Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus Type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob. Agents Chemother. (2003) 47(4):1324-1333.
122. YENI PG, HAMMER SM, CARPENTER CCJ et al.: Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 288:222-235.